The ophthalmic drugs contract manufacturing market is projected to grow at an annualized rate of ~8%.

Comments · 25 Views

Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis

Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

Key Market Insights

  • Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs
  • The market is fragmented, featuring the presence of both established players and small firms based in different geographies that claim to be capable of manufacturing ophthalmic products
  • Presently, majority of the CMOs are offering services for ophthalmic drug FDFs packaged in a variety of formats; popular types of containers include glass / plastic bottles, ointment tubes and ampoules / vials
  • In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities
  • Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and maintain a competitive edge
  • In the past few years, over 10,700 trials, enrolling approximately 4.6 million patients, suffering from a wide range of chronic eye conditions, have been registered across the globe by different sponsors
  • Most of the installed, global ophthalmic drug manufacturing capacity belongs to larger and more established CMOs, accounting for over 80% of available capacity across various geographies
  • The demand for manufacturing services for ophthalmic drug products is expected to increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure consistent supply
  • We expect ophthalmic drug developers to continue to outsource their development and manufacturing operations in the short to mid-term, causing service-based revenues to grow at an annualized rate of over 8%
  • In the long-term, the projected opportunity is anticipated to be well distributed across various packaging formats, scales of operation and sizes of contract service providers
  • Eminent representatives from prominent ophthalmic drug contract manufacturing companies confirm the importance of outsourcing, highlighting prevalent and anticipated trends within this domain

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

Table of Contents

 

  1. PREFACE

1.1.              Scope of the Report

1.2.              Research Methodology

1.3.              Chapter Outlines


  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.              Context and Background

3.2.              Introduction to Ophthalmology

3.2.1.           Chronic Eye Conditions and Associated Economic Burden

 

3.3.              Common Ophthalmic Drug Dosage Forms

3.3.1.           Types of Oral Drug Formulations

3.3.1.1.        Tablets

3.3.1.2.        Capsules

3.3.1.3.        Eye Supplements

 

3.3.2.           Types of Semi-solid Formulations

3.3.2.1.        Ointments

3.5.2.2.        Gels

3.5.2.3.        Emulsions

 

3.3.3.           Types of Liquid Drug Formulations

3.3.3.1.        Solutions

3.3.3.2.        Suspensions

3.5.3.1.        Sterile Injectables

 

3.3.4.           Intraocular Inserts

 

3.4.              Common Primary Packaging Formats for Ophthalmic Drugs

 

3.5.              Overview of Contract Manufacturing

3.6.              Outsourcing in the Ophthalmology Industry

3.6.1.           Need for Outsourcing

3.6.2.           Commonly Outsourced Operations

3.6.3.           Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner

3.6.4.           Advantages of Outsourcing Manufacturing Operations

3.6.5.           Challenges Associated with Ophthalmic Drugs Contract Manufacturing

3.6.6.           Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing

3.6.7.           Recent Developments and Upcoming Trends

 

  1. CURRENT MARKET LANDSCAPE

4.1.              Chapter Overview

4.2.              Ophthalmic Drug Contract Manufacturers: Overall Market Landscape

4.2.1.           Analysis by Year of Establishment

4.2.2.           Analysis by Company Size

4.2.3.           Analysis by Scale of Operation

4.2.4.           Analysis by Geographical Location

4.2.5.           Analysis by Location of Manufacturing Facilities

4.2.6.           Analysis by Type of Product

4.2.7.           Analysis by Type of FDF Manufactured

4.2.8.           Analysis by Type of Primary Packaging

4.2.9.           Analysis by Type of Service(s) Offered

4.2.10.         Analysis by Regulatory Accreditations / Certifications

 

  1. COMPANY COMPETITVENESS ANALYSIS

5.1.              Chapter Overview

5.2.              Key Assumptions and Methodology

5.3.              Competitiveness Analysis: Ophthalmic API Contract Manufacturers

5.3.1.           Ophthalmic API Contract Manufacturers in North America

5.3.2.           Ophthalmic API Contract Manufacturers in Europe

5.3.3.           Ophthalmic API Contract Manufacturers in Asia-Pacific

 

5.4.              Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers

5.4.1.           Ophthalmic Drug FDF Contract Manufacturers in North America

5.4.2.           Ophthalmic Drug FDF Contract Manufacturers in Europe

5.4.3.           Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific

 

  1. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES

6.1.              Chapter Overview

6.2.              Akorn

6.2.1.           Company Overview

6.2.2.           Financial Information

6.2.3.           Service Portfolio

6.2.4.           Recent Developments and Future Outlook

 

6.3.              Catalent

6.3.1.           Company Overview

6.3.2.           Financial Information

6.3.3.           Service Portfolio

6.2.4.           Recent Developments and Future Outlook

 

6.4.              Cayman Chemical

6.4.1.           Company Overview

6.4.2.           Service Portfolio

6.4.3.           Recent Developments and Future Outlook

 

6.5.              Pillar5 Pharma

6.5.1.           Company Overview

6.5.2.           Service Portfolio

6.5.3.           Recent Developments and Future Outlook

 

6.6.              Sterling Pharmaceutical Services

6.6.1.           Company Overview

6.6.2.           Service Portfolio

6.6.3.           Recent Developments and Future Outlook

 

  1. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES

7.1.              Chapter Overview

7.2.              FARMIGEA

7.2.1.           Company Overview

7.2.2.           Service Portfolio

7.2.3.           Recent Developments and Future Outlook

 

7.3.              Lomapharm

7.3.1.           Company Overview

7.3.2.           Service Portfolio

7.3.3            Recent Developments and Future Outlook

 

7.4.              Medichem

7.4.1.           Company Overview

7.4.2.           Service Portfolio

7.4.3.           Recent Developments and Future Outlook

                  

7.5.              Recipharm

7.5.1.           Company Overview

7.5.2.           Financial Information

7.5.3.           Service Portfolio

7.5.4.           Recent Developments and Future Outlook

                  

7.6.              Salvat

7.6.1.           Company Overview

7.6.2            Service Portfolio

7.6.3.           Recent Developments and Future Outlook

 

  1. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES

8.1.              Chapter Overview

8.2.              Akums

8.2.1.           Company Overview

8.2.2.           Service Portfolio

8.2.3.           Recent Developments and Future Outlook

                  

8.3.              Bal Pharma

8.3.1.           Company Overview

8.3.2.           Financial Information

8.3.3.           Service Portfolio

8.2.4.           Recent Developments and Future Outlook

                  

8.4.              Entod Pharmaceuticals

8.4.1.           Company Overview

8.4.2.           Service Portfolio

8.4.3.           Recent Developments and Future Outlook

                  

8.5.              Glenmark Pharmaceuticals

8.5.1.           Company Overview

8.5.2.           Service Portfolio

8.5.3.           Recent Developments and Future Outlook

                  

8.6.              Indiana Ophthalmics

8.6.1.           Company Overview

8.6.2.           Service Portfolio

8.6.3.           Recent Developments and Future Outlook

                  

8.7.              Sunways India

8.7.1.           Company Overview

8.7.2.           Service Portfolio

8.7.3.           Recent Developments and Future Outlook

 

  1. CLINICAL TRIAL ANALYSIS

9.1.              Chapter Overview

9.2.              Scope and Methodology

9.3.              Ophthalmic Drug Trial Analysis

9.3.1.           Analysis by Trial Registration Year

9.3.2.           Geographical Analysis by Number of Clinical Trials

9.3.3.           Geographical Analysis by Enrolled Patient Population

9.3.4.           Analysis by Phase of Development

9.3.5.           Analysis by Trial Recruitment Status

9.3.6.           Analysis by Type of Sponsor / Collaborator

9.3.7.           Most Active Players in Terms of Number of Registered Trials

9.3.8.           Analysis by Type of Intervention

9.3.9.           Analysis by Trial Focus

9.3.10.         Analysis by Target Indication

9.3.11.         Benchmark Analysis of Active Industry Players

 

 

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Comments